You are here

A Novel Small molecule TNF?? inhibitor as a disease-modifying AD drug treatment.

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AG044213-01
Agency Tracking Number: R43AG044213
Amount: $390,959.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIA
Solicitation Number: OD12-003
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
10101 Alliance Rd
United States
DUNS: 182472162
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (513) 475-6618
Business Contact
Phone: (513) 475-6618
Research Institution

DESCRIPTION (provided by applicant): The goal of this application is to develop tumor necrosis factor (TNF )-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). Current FDA-approved AD interventions are symptomatic treatments with limited efficacy which do not affect AD etiology or modify the course of disease progression. Thus, a critical need exists for a novel AD treatment directed towards AD pathophysiology. Recent studies implicate the neuroinflammatory cytokine TNF-as a key mediator in AD-associated neurodegenerative pathology. Multiple preclinical and clinical studies indicate that TNF is a druggable molecular target to modify the course of AD progression. Preliminary Studies demonstrate that our lead compound, IDT, shows potent TNF inhibition in vitro. Preliminary Studies also demosntrate that 100 mg/kg IDT administered orally every day for two months significantly improved working memory in the triple-transgenic (3xTg) AD mouse model. IDT also modulated brain TNF protein levels after daily treatment for two months in AD mice. No morbidity, mortality or any obvious side effects were observed despite the long-term daily treatment regiment with IDT. Taken together, these data strongly suggest that our lead compound is an excellent anti-AD drug candidate. The proposed preclinical study is designed to evaluate the oral efficacy of IDT in 9-month old 3xTg AD mice which mimic moderate symptoms and pathology. Aim 1: Determine the effect of oral administration of IDT mixed in diet on cognitive performance in 3xTg AD mice. Aim 2: Determine the effect of the IDT on TNF- levels, Ass1-40/Ass1-42 levels, microglial activation, synaptophysin and degenerating neurons in 3xTg AD mice. PUBLIC HEALTH RELEVANCE: Alzheimer's Disease (AD) is a significant neurological problem affecting 4.5 million of our senior U.S. citizens. The present research aims to develop an effective drug that can be taken orally to target the underlying neuroinflammation in AD to modify diseaseprogression and improve cognitive function.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government